FDA commissioner Margaret Hamburg says the agency’s priorities for the next five years will be advancing regulatory science and innovation, strengthening the global supply chain safety and integrity, strengthening compliance and enforcement activities to support public health, addressing unmet medical needs of special populations, and advancing medical countermeasures and emergency preparedness.
In an all-hands e-mail, Hamburg says the document “will guide our policies and focus our efforts as we respond to the unprecedented public health challenges of the 21st century.”
For drugs, it sets these goals:

  • Conduct postmarket surveillance to ensure early detection of new safety signals;
  • Conduct rigorous studies to understand new drug safety signals and effectively manage emerging risks;
  • Ensure patient and health professional awareness of drug risks and parameters for safe use; and
  • Oversee drug promotion and marketing to ensure that marketed drug labeling and advertising are truthful and not deemed misleading.

From the August 01, 2011 Issue of MM+M - Medical Marketing and Media